コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 , very low density lipoprotein remnants, and intermediate-density lipoprotein.
2 oteins) and significantly increased VLDL and intermediate density lipoproteins.
3 triacylglycerol (24%), large VLDL (92%), and intermediate-density lipoproteins (53%) and the mean dia
5 sterol, HDL cholesterol, apolipoprotein A-I, intermediate-density lipoprotein and large LDL particles
7 lipoproteins (very low density lipoprotein, intermediate density lipoprotein, and low density lipopr
8 and phospholipid concentrations in the VLDL, intermediate-density lipoprotein, and LDL (P < 0.05-0.01
9 VLDL-apoB (P<0.001 and P.032, respectively), intermediate-density lipoprotein-apoB (P=0.021 and P=.00
10 torvastatin decreased the production rate of intermediate-density lipoprotein-apoB (P=0.043) and LDL-
11 oprotein (VLDL)-apolipoprotein B-100 (apoB), intermediate-density lipoprotein-apoB, and LDL-apoB in 8
12 lesterol; LDL particle count, small LDL, and intermediate-density lipoprotein by nuclear magnetic res
13 beta-arrestin2 increased total and LDL plus intermediate-density lipoprotein cholesterol levels by 2
14 pattern of LDL, lipoprotein(a) cholesterol, intermediate-density lipoprotein cholesterol, high-densi
15 levels and greater cholesterol in VLDLs and intermediate-density lipoproteins compared with subjects
16 ass concentrations of the highly atherogenic intermediate-density lipoprotein fraction in patients wi
18 in (LDL)-, very low-density lipoprotein- and intermediate density lipoprotein (IDL)-related metabolit
19 poprotein B (apoB)-100- and apoB-48-carrying intermediate density lipoproteins (IDL) and low density
20 in very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL)) progressively a
23 L)], elevated remnant cholesterol, increased intermediate-density lipoprotein (IDL) and HDL particle
24 vels increase as a result of accumulation of intermediate-density lipoprotein (IDL) comprising VLDL a
26 e cholesterol content was increased in VLDL, intermediate-density lipoprotein (IDL), and dense LDL fr
28 o induced a decreasing trend in serum total, intermediate-density lipoprotein (IDL), and low-density
30 Human fibroblasts were incubated with model intermediate-density lipoprotein- (IDL-) sized TGRP (10-
31 holesterol and triglyceride content of VLDL, intermediate-density lipoproteins (IDLs), and low-densit
32 ow-density-lipoproteins (VLDL) subfractions, intermediate-density lipoproteins (IDLs), and low-densit
33 hospholipids were elevated in the endogenous intermediate density lipoprotein/LDL of double KO mice a
34 he Pon3KO had significantly increased plasma intermediate-density lipoprotein/LDL cholesterol and bil
35 ceride-rich very low density lipoprotein and intermediate density lipoprotein (lipoprotein B complex)
37 Atherogenic very low density lipoprotein and intermediate density lipoprotein/low density lipoprotein
38 led increased triglyceride concentrations in intermediate density lipoprotein/low density lipoprotein
39 s accounted for by a marked reduction in the intermediate density lipoprotein/low density lipoprotein
40 vely modified form of cholesterol, in plasma intermediate density lipoprotein/low-density lipoprotein
41 icant main effect of treatment for change in intermediate-density lipoprotein particles (IDL-P) after
42 of large HDLNMR particles and total IDLNMR (intermediate-density lipoprotein) particles in subjects
44 g their origin from low-density lipoprotein, intermediate-density lipoprotein, very-low-density lipop
45 m of autologous (125)I-apoB very low density/intermediate density lipoprotein (VLDL/IDL) (fractional
46 the mAb reacted with intact human very-low-/intermediate-density lipoprotein (VLDL/IDL) and low-dens